|
WO2012087965A2
(en)
|
2010-12-22 |
2012-06-28 |
Fate Therapauetics, Inc. |
Cell culture platform for single cell sorting and enhanced reprogramming of ipscs
|
|
JP6261500B2
(ja)
|
2011-07-22 |
2018-01-17 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ヌクレアーゼ切断特異性の評価および改善
|
|
US20150044192A1
(en)
|
2013-08-09 |
2015-02-12 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a cas9 nuclease
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
US9388430B2
(en)
|
2013-09-06 |
2016-07-12 |
President And Fellows Of Harvard College |
Cas9-recombinase fusion proteins and uses thereof
|
|
US20150165054A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting caspase-9 point mutations
|
|
SG11201606934SA
(en)
|
2014-03-04 |
2016-09-29 |
Fate Therapeutics Inc |
Improved reprogramming methods and cell culture platforms
|
|
WO2016022363A2
(en)
|
2014-07-30 |
2016-02-11 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
|
WO2016073955A2
(en)
|
2014-11-06 |
2016-05-12 |
President And Fellows Of Harvard College |
Cells lacking b2m surface expression and methods for allogeneic administration of such cells
|
|
AU2016211671B2
(en)
|
2015-01-26 |
2022-05-26 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
|
EP3294342A4
(en)
|
2015-05-08 |
2018-11-07 |
President and Fellows of Harvard College |
Universal donor stem cells and related methods
|
|
SG10202111851YA
(en)
|
2015-10-16 |
2021-12-30 |
Fate Therapeutics Inc |
Platform for the Induction & Maintenance of Ground State Pluripotency
|
|
JP7109784B2
(ja)
|
2015-10-23 |
2022-08-01 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
遺伝子編集のための進化したＣａｓ９蛋白質
|
|
JP6928604B2
(ja)
|
2015-11-04 |
2021-09-01 |
フェイト セラピューティクス，インコーポレイテッド |
万能性細胞のゲノム改変
|
|
CA3003152A1
(en)
|
2015-11-04 |
2017-05-11 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
|
EP3708587B1
(en)
*
|
2015-11-27 |
2024-05-22 |
Cartherics Pty. Ltd. |
Genetically modified cells and uses thereof
|
|
CA3012042A1
(en)
|
2016-01-26 |
2017-08-03 |
Cedars-Sinai Medical Center |
Systems and methods for in vivo dual recombinase-mediated cassette exchange (drmce) and disease models thereof
|
|
US11377637B2
(en)
|
2016-04-15 |
2022-07-05 |
Memorial Sloan Kettering Cancer Center |
Transgenic T cell and chimeric antigen receptor T cell compositions and related methods
|
|
US11078481B1
(en)
|
2016-08-03 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for screening for cancer targets
|
|
KR102547316B1
(ko)
|
2016-08-03 |
2023-06-23 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
아데노신 핵염기 편집제 및 그의 용도
|
|
US11661590B2
(en)
|
2016-08-09 |
2023-05-30 |
President And Fellows Of Harvard College |
Programmable CAS9-recombinase fusion proteins and uses thereof
|
|
US11542509B2
(en)
|
2016-08-24 |
2023-01-03 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
US11078483B1
(en)
|
2016-09-02 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for measuring and improving CRISPR reagent function
|
|
EP3510145A4
(en)
|
2016-09-06 |
2020-03-25 |
The Children's Medical Center Corporation |
IMMUNCELLS FROM INDUCED PLURIPOTENT STEM CELLS
|
|
EP3526320A1
(en)
|
2016-10-14 |
2019-08-21 |
President and Fellows of Harvard College |
Aav delivery of nucleobase editors
|
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
|
CN110177869A
(zh)
*
|
2017-01-13 |
2019-08-27 |
加利福尼亚大学董事会 |
免疫改造的多能细胞
|
|
CN110546265A
(zh)
|
2017-02-09 |
2019-12-06 |
因达普塔治疗公司 |
工程化自然杀伤(nk)细胞及其组合物和方法
|
|
JP2020510038A
(ja)
|
2017-03-09 |
2020-04-02 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
がんワクチン
|
|
EP3592853A1
(en)
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Suppression of pain by gene editing
|
|
JP2020510439A
(ja)
|
2017-03-10 |
2020-04-09 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
シトシンからグアニンへの塩基編集因子
|
|
CN110637083A
(zh)
*
|
2017-03-20 |
2019-12-31 |
华盛顿大学 |
细胞及其使用和制备方法
|
|
CA3057192A1
(en)
|
2017-03-23 |
2018-09-27 |
President And Fellows Of Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
|
WO2018195175A1
(en)
*
|
2017-04-18 |
2018-10-25 |
FUJIFILM Cellular Dynamics, Inc. |
Antigen-specific immune effector cells
|
|
WO2018209320A1
(en)
|
2017-05-12 |
2018-11-15 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
|
|
CA3065126A1
(en)
*
|
2017-06-01 |
2018-12-06 |
Innovative Cellular Therapeutics CO., LTD. |
Chimeric antigen receptor cell preparation and uses thereof
|
|
CA3067382A1
(en)
|
2017-06-15 |
2018-12-20 |
The Regents Of The University Of California |
Targeted non-viral dna insertions
|
|
WO2019023680A1
(en)
|
2017-07-28 |
2019-01-31 |
President And Fellows Of Harvard College |
METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE)
|
|
CA3071683A1
(en)
*
|
2017-08-08 |
2019-02-14 |
Sangamo Therapeutics, Inc. |
Chimeric antigen receptor mediated cell targeting
|
|
EP3441461A1
(en)
*
|
2017-08-11 |
2019-02-13 |
Baylor College of Medicine |
Cd1d-restricted nkt cells as a platform for off-the-shelf cancer immunotherapy
|
|
EP3676376B1
(en)
|
2017-08-30 |
2025-01-15 |
President and Fellows of Harvard College |
High efficiency base editors comprising gam
|
|
KR20250107288A
(ko)
|
2017-10-16 |
2025-07-11 |
더 브로드 인스티튜트, 인코퍼레이티드 |
아데노신 염기 편집제의 용도
|
|
KR20200075851A
(ko)
*
|
2017-10-19 |
2020-06-26 |
셀렉티스 |
개선된 면역 세포들 치료를 위한 nk 억제제들의 타겟인 유전자 통합
|
|
GB201717524D0
(en)
|
2017-10-25 |
2017-12-06 |
Autolus Ltd |
Vectors
|
|
KR102503130B1
(ko)
|
2017-10-27 |
2023-02-24 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
내인성 t 세포 수용체의 표적화된 대체
|
|
CN108118069A
(zh)
*
|
2017-11-06 |
2018-06-05 |
深圳市三启生物技术有限公司 |
新的模拟阿尔茨海默病的人诱导多潜能干细胞系及其用途
|
|
US20200407713A1
(en)
*
|
2017-11-16 |
2020-12-31 |
Mogam Institute For Biomedical Research |
Transformed human cell and use thereof
|
|
CN111356463A
(zh)
*
|
2017-11-20 |
2020-06-30 |
学校法人庆应义塾 |
使用多能干细胞的自杀基因脑肿瘤治疗药
|
|
US20210015859A1
(en)
*
|
2017-12-08 |
2021-01-21 |
Fate Therapeutics, Inc. |
IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS
|
|
WO2019118949A1
(en)
|
2017-12-15 |
2019-06-20 |
The Broad Institute, Inc. |
Systems and methods for predicting repair outcomes in genetic engineering
|
|
CA3083779A1
(en)
*
|
2017-12-22 |
2019-06-27 |
Fate Therapeutics, Inc. |
Enhanced immune effector cells and use thereof
|
|
US12258571B2
(en)
|
2018-03-16 |
2025-03-25 |
Cedars-Sinai Medical Center |
Methods and compositions for inducible expression of neurotrophic factors
|
|
JP7575271B2
(ja)
*
|
2018-03-29 |
2024-10-29 |
フェイト セラピューティクス，インコーポレイテッド |
操作された免疫エフェクター細胞およびその使用
|
|
EP3797160A1
(en)
|
2018-05-23 |
2021-03-31 |
The Broad Institute Inc. |
Base editors and uses thereof
|
|
AU2019287483B2
(en)
*
|
2018-06-12 |
2024-03-14 |
The Regents Of The University Of California |
Stem cell-engineered iNKT cell-based off-the-shelf cellular therapy
|
|
US12522807B2
(en)
|
2018-07-09 |
2026-01-13 |
The Broad Institute, Inc. |
RNA programmable epigenetic RNA modifiers and uses thereof
|
|
US20210308183A1
(en)
*
|
2018-07-17 |
2021-10-07 |
The Regents Of The University Of California |
Chimeric antigen receptor t cells derived from immunoengineered pluripotent stem cells
|
|
BR112021000637A2
(pt)
*
|
2018-07-17 |
2021-04-13 |
The Regents Of The University Of California |
Célula cardíaca hipoimune isolada, método para tratar um paciente que sofre de uma afecção ou doença cardíaca, método para produzir uma população de células cardíacas hipoimunes, célula endotelial hipoimune isolada, método para tratar um paciente que sofre de uma afecção ou doença vascular, método para produzir uma população de células endoteliais hipoimunes, neurônio dopaminérgico hipoimune isolado, método para tratar um paciente que sofre de uma doença ou afecção neurodegenerativa, método para produzir uma população de neurônios dopaminérgicos hipoimunes, célula de ilhota pancreática hipoimune isolada, método para tratar um paciente que sofre de diabetes, método para produzir uma população de células de ilhota pancreática hipoimunes, célula de epitélio pigmentado da retina (rpe) hipoimune isolada, método para tratar um paciente que sofre de uma afecção ocular, e método para produzir uma população de células de epitélio pigmentado da retina (rpe) hipoimunes
|
|
US20210275596A1
(en)
*
|
2018-07-20 |
2021-09-09 |
Cell2In, Inc. |
Application of gene profile for cells isolated using fresh-tracer
|
|
CN112752838A
(zh)
*
|
2018-07-26 |
2021-05-04 |
国立大学法人京都大学 |
制备引入外源抗原受体的细胞的方法
|
|
CN108913754A
(zh)
*
|
2018-07-26 |
2018-11-30 |
苏州呼呼健康科技有限公司 |
精子端粒长度的检测试剂、试剂盒及应用与检测方法
|
|
JP7541508B2
(ja)
*
|
2018-08-23 |
2024-08-28 |
サンガモ セラピューティクス， インコーポレイテッド |
操作された標的特異的な塩基エディター
|
|
US12378572B2
(en)
*
|
2018-09-07 |
2025-08-05 |
Crispr Therapeutics Ag |
Universal donor cells
|
|
CN109136192A
(zh)
*
|
2018-09-20 |
2019-01-04 |
北京呈诺医学科技有限公司 |
一种iCAR-NK细胞的制备方法
|
|
CN113195724A
(zh)
*
|
2018-09-26 |
2021-07-30 |
新加坡国立大学 |
低免疫原性的工程化人类间充质基质细胞，制备方法和试剂盒
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
CN109266618B
(zh)
*
|
2018-10-18 |
2021-04-23 |
赛元生物科技(杭州)有限公司 |
能够靶向肿瘤细胞的巨噬细胞及其制备方法
|
|
WO2020092453A1
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
|
US12410402B2
(en)
|
2018-11-21 |
2025-09-09 |
Indapta Therapeutics, Inc. |
Methods for expansion of natural killer (NK) cell subset and related compositions and methods
|
|
US12590148B2
(en)
|
2018-11-26 |
2026-03-31 |
Nkarta, Inc. |
Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
|
|
US20220023348A1
(en)
*
|
2018-11-28 |
2022-01-27 |
Forty Seven, Inc. |
Genetically modified hspcs resistant to ablation regime
|
|
CN111424016A
(zh)
*
|
2019-01-09 |
2020-07-17 |
复旦大学 |
降低细胞免疫原性的诱导型多能干细胞系及建立方法
|
|
US12351837B2
(en)
|
2019-01-23 |
2025-07-08 |
The Broad Institute, Inc. |
Supernegatively charged proteins and uses thereof
|
|
EP3924467A1
(en)
*
|
2019-02-15 |
2021-12-22 |
Editas Medicine, Inc. |
Modified natural killer (nk) cells for immunotherapy
|
|
KR20210128440A
(ko)
*
|
2019-02-15 |
2021-10-26 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
범용 공여자 줄기 세포 및 관련 방법
|
|
JP7491589B2
(ja)
*
|
2019-02-22 |
2024-05-28 |
国立大学法人 鹿児島大学 |
ヒト多能性幹細胞の安全領域に長い外来遺伝子を組み込み正常機能させる方法
|
|
AU2020232691B2
(en)
|
2019-03-05 |
2023-06-29 |
Nkarta, Inc. |
CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
|
|
JP7657726B2
(ja)
|
2019-03-19 |
2025-04-07 |
ザ ブロード インスティテュート，インコーポレーテッド |
編集ヌクレオチド配列を編集するための方法および組成物
|
|
JP7286796B2
(ja)
*
|
2019-04-03 |
2023-06-05 |
プレシジョン バイオサイエンシズ，インク． |
マイクロｒｎａ適合ｓｈｒｎａ（ｓｈｒｎａｍｉｒ）を含む遺伝子改変免疫細胞
|
|
AU2020271523A1
(en)
*
|
2019-04-11 |
2021-10-14 |
Fate Therapeutics, Inc. |
CD3 reconstitution in engineered iPSC and immune effector cells
|
|
US12473543B2
(en)
|
2019-04-17 |
2025-11-18 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
US11162079B2
(en)
|
2019-05-10 |
2021-11-02 |
The Regents Of The University Of California |
Blood type O Rh-hypo-immunogenic pluripotent cells
|
|
WO2020231882A2
(en)
|
2019-05-10 |
2020-11-19 |
The Regents Of The University Of California |
Modified pluripotent cells
|
|
CN110305899A
(zh)
*
|
2019-06-25 |
2019-10-08 |
华中农业大学 |
外源基因定点整合至gapdh基因下游的打靶载体构建方法及其应用
|
|
TW202115245A
(zh)
*
|
2019-06-27 |
2021-04-16 |
丹麥商諾佛 儂迪克股份有限公司 |
安全免疫隱形細胞
|
|
BR112022000641A2
(pt)
*
|
2019-07-17 |
2022-03-29 |
Fate Therapeutics Inc |
Modificação genética de célula efetora imune e uso da mesma
|
|
GB201911957D0
(en)
*
|
2019-08-20 |
2019-10-02 |
Adaptimmune Ltd |
Methods of producing haemogenic progenitor cells from pluripotent stem cells
|
|
KR20220058579A
(ko)
|
2019-09-05 |
2022-05-09 |
크리스퍼 테라퓨틱스 아게 |
보편적 공여자 세포
|
|
US11104918B2
(en)
*
|
2019-09-05 |
2021-08-31 |
Crispr Therapeutics Ag |
Universal donor cells
|
|
CA3149585A1
(en)
*
|
2019-09-25 |
2021-04-01 |
Bahram VALMEHR |
Multi-targeting effector cells and use thereof
|
|
BR112022006440A2
(pt)
*
|
2019-10-07 |
2022-07-05 |
Fate Therapeutics Inc |
Receptor de antígeno quimérico intensificado para manipulação de célula efetora imune e uso do mesmo
|
|
US12435330B2
(en)
|
2019-10-10 |
2025-10-07 |
The Broad Institute, Inc. |
Methods and compositions for prime editing RNA
|
|
AU2020364139A1
(en)
*
|
2019-10-10 |
2022-05-26 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Modified stem cells and methods of use thereof
|
|
JP2022551975A
(ja)
*
|
2019-10-15 |
2022-12-14 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Ｆｃ封鎖を介する移植細胞保護
|
|
EP4045539A4
(en)
*
|
2019-10-17 |
2024-03-13 |
Fate Therapeutics, Inc. |
Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof
|
|
AU2020393334A1
(en)
*
|
2019-11-25 |
2022-06-16 |
Kyoto University |
T-cell master cell bank
|
|
MX2022006725A
(es)
*
|
2019-12-06 |
2022-08-22 |
Fate Therapeutics Inc |
Mejora de célula inmunitaria efectora derivada de ipsc mediante el uso de compuestos pequeños.
|
|
NZ789406A
(en)
*
|
2019-12-27 |
2026-03-27 |
Zhaotai Immugene Biomedicine Hong Kong Ltd |
Engineered immune killer cell, preparation method therefor and use thereof
|
|
US20210254005A1
(en)
*
|
2020-01-23 |
2021-08-19 |
Kangstem Biotech Co., Ltd. |
Off-the-shelf stem cell and immune cell, and a pharmaceutical composition including the same
|
|
WO2021173449A1
(en)
*
|
2020-02-25 |
2021-09-02 |
The Board Of Trustees Of The Leland Stanford Junior University |
Orthogonal safety switches to eliminate genetically engineered cells
|
|
EP4127143A1
(en)
*
|
2020-04-03 |
2023-02-08 |
Progenitor Life Sciences |
Targeting tapasin and tap complex to improve cellular immune-compatibility
|
|
DE112021002672T5
(de)
|
2020-05-08 |
2023-04-13 |
President And Fellows Of Harvard College |
Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz
|
|
EP4159846A4
(en)
*
|
2020-05-26 |
2024-08-14 |
Healios K.K. |
HYPOIMMUNOGENIC CELLS
|
|
WO2021251271A1
(ja)
*
|
2020-06-09 |
2021-12-16 |
帝人株式会社 |
Ｍｈｃ－クラスｉ発現が抑制された細胞
|
|
AU2021292695A1
(en)
*
|
2020-06-19 |
2023-02-02 |
Fate Therapeutics, Inc. |
Combining iPSC-derived effector cell types for immunotherapy use
|
|
CN114350612A
(zh)
*
|
2020-09-28 |
2022-04-15 |
未来智人再生医学研究院(广州)有限公司 |
表达靶向CTLA-4的shRNA/shRNA-miR的多能干细胞或其衍生物
|
|
CN114276995A
(zh)
*
|
2020-09-28 |
2022-04-05 |
未来智人再生医学研究院(广州)有限公司 |
一种表达ctla-4阻遏分子的多能干细胞及其衍生物
|
|
CA3194577A1
(en)
*
|
2020-10-09 |
2022-04-14 |
Sonja SCHREPFER |
Methods for triggering safety killing mechanisms using a cd47-sirp.alpha. blockade agent
|
|
IL302315A
(en)
*
|
2020-10-26 |
2023-06-01 |
Arsenal Biosciences Inc |
Secure port sites
|
|
CN114507643A
(zh)
*
|
2020-10-29 |
2022-05-17 |
未来智人再生医学研究院(广州)有限公司 |
一种表达il-2的多能干细胞衍生物及应用
|
|
CN114457021A
(zh)
*
|
2020-10-30 |
2022-05-10 |
未来智人再生医学研究院(广州)有限公司 |
一种表达cd47抗体的多能干细胞及其衍生物与应用
|
|
CN114457029A
(zh)
*
|
2020-10-30 |
2022-05-10 |
未来智人再生医学研究院(广州)有限公司 |
一种表达vegf-a阻断物的多能干细胞或其衍生物及应用
|
|
CN114517184A
(zh)
*
|
2020-10-30 |
2022-05-20 |
未来智人再生医学研究院(广州)有限公司 |
一种表达adipsin的多能干细胞或其衍生物及应用
|
|
CN114525254A
(zh)
*
|
2020-10-30 |
2022-05-24 |
未来智人再生医学研究院(广州)有限公司 |
一种表达fgf-21的多能干细胞或其衍生物及应用
|
|
CN114525257A
(zh)
*
|
2020-10-30 |
2022-05-24 |
未来智人再生医学研究院(广州)有限公司 |
一种表达Tim-3阻断物的多能干细胞或其衍生物及应用
|
|
CN114525256A
(zh)
*
|
2020-10-30 |
2022-05-24 |
未来智人再生医学研究院(广州)有限公司 |
一种表达Siglec-15阻断物的多能干细胞或其衍生物及应用
|
|
CN114457028A
(zh)
*
|
2020-10-30 |
2022-05-10 |
未来智人再生医学研究院(广州)有限公司 |
一种表达cd38抗体的多能干细胞及其衍生物与应用
|
|
CN114457033A
(zh)
*
|
2020-10-30 |
2022-05-10 |
未来智人再生医学研究院(广州)有限公司 |
一种表达il-6阻断物的多能干细胞衍生物及其应用
|
|
CN114525255A
(zh)
*
|
2020-10-30 |
2022-05-24 |
未来智人再生医学研究院(广州)有限公司 |
一种表达il-11的多能干细胞衍生物及其应用
|
|
CN114457030A
(zh)
*
|
2020-10-30 |
2022-05-10 |
未来智人再生医学研究院(广州)有限公司 |
一种表达IgE阻断物的多能干细胞或其衍生物及应用
|
|
CN114457034A
(zh)
*
|
2020-10-30 |
2022-05-10 |
未来智人再生医学研究院(广州)有限公司 |
一种表达il-1阻断物的多能干细胞衍生物及其应用
|
|
CN114457024A
(zh)
*
|
2020-10-30 |
2022-05-10 |
未来智人再生医学研究院(广州)有限公司 |
一种表达IL-4Rα阻断物的多能干细胞或其衍生物及应用
|
|
CN114457027A
(zh)
*
|
2020-10-30 |
2022-05-10 |
未来智人再生医学研究院(广州)有限公司 |
一种表达Amyloidβ抗体的多能干细胞及其衍生物与应用
|
|
CN114457026A
(zh)
*
|
2020-10-30 |
2022-05-10 |
未来智人再生医学研究院(广州)有限公司 |
一种表达4-1bb激活型抗体的多能干细胞及其衍生物与应用
|
|
WO2022115492A1
(en)
*
|
2020-11-24 |
2022-06-02 |
Lyell Immunopharma, Inc. |
Methods for making, compositions comprising, and methods of using rejuvenated t cells
|
|
US11591381B2
(en)
|
2020-11-30 |
2023-02-28 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
|
AU2021392032A1
(en)
|
2020-12-03 |
2023-06-22 |
Century Therapeutics, Inc. |
Genetically engineered cells and uses thereof
|
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
|
CN116981685A
(zh)
*
|
2020-12-03 |
2023-10-31 |
世纪治疗股份有限公司 |
基因工程化细胞及其用途
|
|
CN114645018A
(zh)
*
|
2020-12-18 |
2022-06-21 |
未来智人再生医学研究院(广州)有限公司 |
一种表达cd38靶向抑制因子的多能干细胞及其衍生物与应用
|
|
WO2022129472A1
(en)
*
|
2020-12-18 |
2022-06-23 |
Novo Nordisk A/S |
Safe immuno-stealth cells
|
|
AR124414A1
(es)
|
2020-12-18 |
2023-03-22 |
Century Therapeutics Inc |
Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
|
|
WO2022136215A1
(en)
*
|
2020-12-21 |
2022-06-30 |
Novo Nordisk A/S |
Safe immuno-stealth cells
|
|
CN114645021A
(zh)
*
|
2020-12-21 |
2022-06-21 |
未来智人再生医学研究院(广州)有限公司 |
一种表达靶向cd47抑制因子的多能干细胞及其衍生物与应用
|
|
CN114657131A
(zh)
*
|
2020-12-22 |
2022-06-24 |
未来智人再生医学研究院(广州)有限公司 |
一种表达尿酸氧化酶的多能干细胞或其衍生物
|
|
CN114657134A
(zh)
*
|
2020-12-22 |
2022-06-24 |
未来智人再生医学研究院(广州)有限公司 |
一种表达靶向IgE的shRNA和/或shRNA-miR的多能干细胞或其衍生物
|
|
CN114657130A
(zh)
*
|
2020-12-22 |
2022-06-24 |
未来智人再生医学研究院(广州)有限公司 |
一种表达vegf-a靶向抑制因子的多能干细胞及其衍生物与应用
|
|
CN114717193A
(zh)
*
|
2020-12-22 |
2022-07-08 |
未来智人再生医学研究院(广州)有限公司 |
一种表达靶向B7-H5的shRNA和/或shRNA-miR的多能干细胞或其衍生物
|
|
CN114657136A
(zh)
*
|
2020-12-22 |
2022-06-24 |
未来智人再生医学研究院(广州)有限公司 |
一种表达靶向PCSK9的shRNA和/或shRNA-miR的多能干细胞或其衍生物
|
|
CN114717232A
(zh)
*
|
2020-12-22 |
2022-07-08 |
未来智人再生医学研究院(广州)有限公司 |
表达irf-1靶向抑制因子的多能干细胞及其衍生物与应用
|
|
CN114657138A
(zh)
*
|
2020-12-22 |
2022-06-24 |
未来智人再生医学研究院(广州)有限公司 |
一种表达靶向B7-H4的shRNA和/或shRNA-miR的多能干细胞或其衍生物
|
|
CN114717192A
(zh)
*
|
2020-12-22 |
2022-07-08 |
未来智人再生医学研究院(广州)有限公司 |
一种表达Amyloidβ靶向抑制因子的多能干细胞及其衍生物与应用
|
|
CN114657133A
(zh)
*
|
2020-12-22 |
2022-06-24 |
未来智人再生医学研究院(广州)有限公司 |
一种表达靶向IL-4 Rα的shRNA和/或shRNA-miR的多能干细胞
|
|
WO2022144632A1
(en)
|
2020-12-30 |
2022-07-07 |
Crispr Therapeutics Ag |
Compositions and methods for differentiating stem cells into nk cells
|
|
KR20230146007A
(ko)
|
2020-12-31 |
2023-10-18 |
크리스퍼 테라퓨틱스 아게 |
범용 공여자 세포
|
|
KR102766602B1
(ko)
*
|
2021-02-05 |
2025-02-13 |
의료법인 성광의료재단 |
다능성 줄기세포 유래 조혈 내피세포를 이용한 유전자 편집된 세포의 제조방법
|
|
EP4298205A1
(en)
*
|
2021-02-23 |
2024-01-03 |
Poseida Therapeutics, Inc. |
Genetically modified induced pluripotent stem cells and methods of use thereof
|
|
CN117377756A
(zh)
*
|
2021-03-05 |
2024-01-09 |
菲克特生物科学股份有限公司 |
工程化免疫细胞疗法
|
|
IL307219A
(en)
*
|
2021-03-31 |
2023-11-01 |
Garuda Therapeutics Inc |
Pluripotent stem cell-derived hematopoietic lineages
|
|
CN117120598A
(zh)
*
|
2021-04-12 |
2023-11-24 |
梅德基因治疗公司 |
激活和增殖暴露于抗原的cd8 t细胞的方法、由此制备的具有增强的抗癌活性的cd8 t细胞及其用途
|
|
CN115485367B
(zh)
*
|
2021-04-16 |
2023-09-12 |
杭州启函生物科技有限公司 |
用于细胞工程的安全港基因座
|
|
AU2022299551A1
(en)
*
|
2021-06-23 |
2024-01-18 |
Editas Medicine, Inc. |
Engineered cells for therapy
|
|
JP2024524626A
(ja)
*
|
2021-07-09 |
2024-07-05 |
シュプレム |
操作された寡能性幹細胞から分化した細胞を含む食料品
|
|
EP4370697A4
(en)
*
|
2021-07-12 |
2026-02-25 |
Childrens Hospital Med Ct |
DIFFERENTIAL EXPRESSION OF CXCR4 ON HEMATOPOIETIC PROGENITOR CELLS COMPARED TO DIRECT ECOTROPISM AND LONG-TERM STEM CELL ENGRAVING
|
|
US20250082686A1
(en)
|
2021-07-21 |
2025-03-13 |
Aspen Neuroscience, Inc. |
Aav-based modulation of gba1 and related compositions and uses thereof
|
|
WO2023004366A1
(en)
|
2021-07-21 |
2023-01-26 |
Aspen Neuroscience, Inc. |
Transposon-based modulation of gba1 and related compositions and uses thereof
|
|
EP4395838A1
(en)
*
|
2021-08-30 |
2024-07-10 |
CarryGenes Bioengineering, LLC |
tCD34 AND OTHER MARKERS FOR IDENTIFICATION AND SORTING OF CELLS AND FOR USE ASIN VIVO TRACKING ASSISTANT
|
|
AU2022366987A1
(en)
|
2021-10-14 |
2024-05-16 |
Arsenal Biosciences, Inc. |
Immune cells having co-expressed shrnas and logic gate systems
|
|
IL312752A
(en)
*
|
2021-11-12 |
2024-07-01 |
Targetgene Biotechnologies Ltd |
Systems and methods for trans-modulation of immune cells by genetic manipulation of immune regulatory genes
|
|
WO2023116929A1
(en)
*
|
2021-12-24 |
2023-06-29 |
Hemacell Therapeutics Inc. |
Method for producing human induced pluripotent stem cells through homologous recombination and integrase-mediated recombination
|
|
KR20240128067A
(ko)
*
|
2021-12-29 |
2024-08-23 |
브리스톨-마이어스 스큅 컴퍼니 |
랜딩 패드 세포주의 생성
|
|
US20260000761A1
(en)
*
|
2022-01-19 |
2026-01-01 |
Nkarta, Inc. |
Engineered immune cells with enhanced potency and uses of same in immunotherapy
|
|
WO2023167575A1
(ko)
*
|
2022-03-04 |
2023-09-07 |
주식회사 툴젠 |
저면역원성 줄기세포, 줄기세포로부터 분화되거나 유래된 저면역원성 세포 및 이의 제조방법
|
|
CN119562762A
(zh)
|
2022-04-04 |
2025-03-04 |
加利福尼亚大学董事会 |
遗传互补组合物和方法
|
|
CN119365492A
(zh)
*
|
2022-05-04 |
2025-01-24 |
世纪治疗股份有限公司 |
用hla-e和hla-g转基因工程化的细胞
|
|
EP4522201A1
(en)
|
2022-05-09 |
2025-03-19 |
Synteny Therapeutics, Inc. |
Erythroparvovirus compositions and methods for gene therapy
|
|
EP4522210A1
(en)
|
2022-05-09 |
2025-03-19 |
Synteny Therapeutics, Inc. |
Erythroparvovirus with a modified genome for gene therapy
|
|
WO2023220040A1
(en)
|
2022-05-09 |
2023-11-16 |
Synteny Therapeutics, Inc. |
Erythroparvovirus with a modified capsid for gene therapy
|
|
WO2024023802A2
(en)
*
|
2022-07-29 |
2024-02-01 |
Crispr Therapeutics Ag |
Genetically engineered immune cells having disrupted transporter associated with antigen processing-2 (tap-2) gene
|
|
CN120641557A
(zh)
*
|
2022-10-05 |
2025-09-12 |
迦鲁达细胞疗法公司 |
来源于多能细胞的红系谱系
|
|
WO2024102860A1
(en)
*
|
2022-11-09 |
2024-05-16 |
Shoreline Biosciences, Inc. |
Engineered cells for therapy
|
|
CN116334082B
(zh)
*
|
2023-02-15 |
2024-11-26 |
深圳市济因生物科技有限公司 |
一种CD16a基因敲除的NK细胞及其制备方法与应用
|
|
US12383615B2
(en)
|
2023-03-23 |
2025-08-12 |
Carbon Biosciences, Inc. |
Protoparvovirus compositions comprising a protoparvovirus variant VP1 capsid polypeptide and related methods
|
|
EP4683931A1
(en)
|
2023-03-23 |
2026-01-28 |
Carbon Biosciences, Inc. |
Parvovirus compositions and related methods for gene therapy
|
|
WO2024197552A1
(en)
*
|
2023-03-28 |
2024-10-03 |
Nuwacell Biotechnologies Co., Ltd. |
Genetically-modified pluripotent stem cells and derived natural killer cells and methods for producing the same
|
|
WO2025257133A1
(en)
|
2024-06-14 |
2025-12-18 |
Universität Zürich |
Gene-edited pluripotent stem cells for tissue engineering
|
|
WO2026072721A1
(en)
|
2024-09-25 |
2026-04-02 |
Carbon Biosciences, Inc. |
Parvovirus compositions and methods for gene therapy
|